Eribulin Injection [Halaven] + Paclitaxel injection
ApprovedUNKNOWN 2 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Breast Cancer Female
Conditions
Breast Cancer Female, Neoplasm, Breast, Breast Cancer Metastatic
Trial Timeline
Mar 11, 2021 → Sep 15, 2023
NCT ID
NCT05033769About Eribulin Injection [Halaven] + Paclitaxel injection
Eribulin Injection [Halaven] + Paclitaxel injection is a approved stage product being developed by Eisai for Breast Cancer Female. The current trial status is unknown. This product is registered under clinical trial identifier NCT05033769. Target conditions include Breast Cancer Female, Neoplasm, Breast, Breast Cancer Metastatic.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer Female were approved
Approved (20) Terminated (5) Active (0)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05033769 | Approved | UNKNOWN |
Competing Products
20 competing products in Breast Cancer Female